British Journal of Anaesthesia, 2004, Vol. 92, No. 3 335-343
© 2004 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers
1 Department of Anesthesiology, 3C444, University of Utah Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA. 2 Clinical Pharmacology, Glaxo Research Institute (now GlaxoSmithKline)
*Corresponding author. E-mail: talmage.egan@hsc.utah.edu 
Declaration of interest. Dr Egan has received research funding, consultancy fees and speaking honoraria from GlaxoWellcome (the original developers of remifentanil; now GlaxoSmithKline) and Abbott Laboratories (the current marketers of remifentanil in the USA). The work, supported in part by a grant from GlaxoWellcome Research Institute administered through the Utah Pain Research Foundation, was performed entirely at the University of Utah Health Sciences Center, Salt Lake City, UT.
Background. Although remifentanil’s short-acting pharmacokinetic profile makes it well suited for procedures during which a brief period of intense analgesia is required, setting up an infusion pump for brief procedures is inconvenient. The clinical pharmacology of remifentanil administered by bolus injection, a more convenient alternative, has not been explored in detail. The primary aim of this study was to examine the safety of single bolus doses of remifentanil in conscious, healthy, adult volunteers breathing room air. Secondary aims included the evaluation of remifentanil pharmacokinetics and analgesic effects after bolus injection and a comparison of these issues in younger vs older adults.
Methods. Using a randomized, double-blind, placebo-controlled, dose-escalation, crossover study design, 64 subjects (16 over 60 years old) received remifentanil or placebo by bolus injection in a fixed unit dose separated by a 1 h washout period. Respiratory effects were assessed using a respiratory intervention scale. Analgesic effects were assessed using pressure algometry. A population pharmacokinetic model was constructed using non-linear, mixed-effects modelling techniques based on arterial blood samples. Computer simulations were performed to illustrate the clinical application of the pharmacokinetic model.
Results. Dose-related increases in both respiratory and analgesic effects were observed. In general, the respiratory depression observed was mild and easily treated with requests to breathe or the administration of oxygen, although the older cohort (and some younger subjects) experienced more substantial respiratory depression at lower doses. The pharmacokinetics of bolus-dose remifentanil were adequately described by a two-compartment model. The pharmacokinetic simulations illustrated the potential utility of bolus-dose remifentanil.
Conclusions. Bolus injection could potentially be a safe and effective means of administering remifentanil in clinical situations requiring a brief period of intense analgesia. Because some subjects, both old and young, experienced significant respiratory depression even at low doses, careful monitoring of respiratory function is essential.
Br J Anaesth 2004; 92: 335–43
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-R. Lee, C.-W. Jung, and Y.-H. Lee Reduction of pain during induction with target-controlled propofol and remifentanil Br. J. Anaesth., December 1, 2007; 99(6): 876 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Koo, S. H. Choi, D. H. Chun, H. K. Kil, K. J. Kim, K. T. Min, and S. J. Lee Respiratory Depression Caused by Remifentanil Infusion for Postoperative Pain Control Anesth. Analg., December 1, 2006; 103(6): 1627 - 1628. [Full Text] [PDF]
|
|
|
|
|
|
I. Volikas, A. Butwick, C. Wilkinson, A. Pleming, and G. Nicholson Maternal and neonatal side-effects of remifentanil patient-controlled analgesia in labour Br. J. Anaesth., October 1, 2005; 95(4): 504 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Medina, E. M. Galvin, M. Dirckx, P. Banwarie, J. F. H. Ubben, F. J. Zijlstra, J. Klein, and S. J. C. Verbrugge Remifentanil as a Single Drug for Extracorporeal Shock Wave Lithotripsy: A Comparison of Infusion Doses in Terms of Analgesic Potency and Side Effects Anesth. Analg., August 1, 2005; 101(2): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mallick, S. Elliot, T. D. Egan, and S. E. Kern Remifentanil is too potent to be given by bolus Br. J. Anaesth., August 1, 2004; 93(2): 305 - 306. [Full Text] [PDF]
|
|